Aquestive Therapeutics (AQST) Proxy filing summary

Executive summary

• The 2026 Annual Meeting will be held virtually on June 10, 2026, with stockholders able to participate online and vote on key proposals.

• Stockholders will vote on electing three Class II directors, approving executive compensation on an advisory basis, and ratifying the appointment of KPMG LLP as the independent auditor for 2026.

• The Board recommends voting in favor of all proposals and highlights the company's focus on advancing proprietary products and long-term value creation.

Voting matters and shareholder proposals

• Proposals include electing Gregory B. Brown, M.D., John S. Cochran, and Abigail L. Jenkins as Class II directors for three-year terms.

• Advisory vote on executive compensation (say-on-pay) is held annually, with the Board recommending approval.

• Ratification of KPMG LLP as independent registered public accounting firm for fiscal year 2026.

• Stockholders may submit proposals and director nominations for future meetings per company bylaws.

Board of directors and corporate governance

• The Board consists of seven members, six of whom are independent; directors are divided into three classes with staggered terms.

• Board committees include Audit, Compensation, Nominating and Corporate Governance, and Science and Technology, each with defined responsibilities.

• The Chair and CEO roles are separated to reinforce board independence.

• Non-employee directors receive cash retainers and annual equity grants; all directors attended at least 75% of meetings in 2025.